ライフサイエンスコーパス: human immunoglobulin

1 tions of foscarnet, and anti-Cytomegalovirus human immunoglobulin.

2 tooligosaccharides and branched glycans from human immunoglobulin.

3 eutralizing titer with pooled plasma-derived human immunoglobulin.

4 s treated contemporaneously with nonspecific human immunoglobulin.

5 he B7-CD28 costimulatory pathway, or control human immunoglobulin (200 microg) on the day of transpla

6 Human immunoglobulin A (IgA) is an abundant antibody tha

7 Human immunoglobulin A (IgA) is the most prevalent antib

8 BCP also binds human immunoglobulin A (IgA), a characteristic that may

9 al, in that it exhibited specific binding to human immunoglobulin A (IgA), IgD, and IgG in addition t

10 enzymes have convergently evolved to cleave human immunoglobulin A as a means of modulating and evad

11 Components of the human immunoglobulin A1 (IgA1) hinge governing sensitivi

12 a zinc metalloproteinase, Iga, which cleaves human immunoglobulin A1 (IgA1), and whose activity is pr

13 crete site-specific proteases able to cleave human immunoglobulin A1 (IgA1), the first line of defens

14 ococcus expresses a protease that hydrolyzes human immunoglobulin A1 (IgA1).

15 Human immunoglobulin administered intraperitoneally at t

16 o the human HAVCR1/TIM1 Fc contained cDNA of human immunoglobulin alpha 1 heavy (Igalpha1) and lambda

17 e application of the new method by analyzing human immunoglobulin and Drosophilid alcohol dehydrogena

18 assessed by change in levels of circulating human immunoglobulins and by histologic examinations.

19 , which is confirmed by depletion studies of human immunoglobulins and by mouse immunizations.

20 omponents were confirmed by the detection of human immunoglobulins and human interleukin-6 in serum s

21 are detected with fluorescently labeled anti-human immunoglobulin antibody and flow analysis in a dua

22 donkeys, rats, and mice) and the binding to human immunoglobulins appears to be immunoglobulin G (Ig

23 in lateral flow assays for the detection of human immunoglobulin as a model protein.

24 mmunoglobulins and rabbit antibodies against human immunoglobulins, but not into immunoprecipitates f

25 Within 25 kb downstream of both the human immunoglobulin Calpha1 and Calpha2 genes we identi

26 the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indic

27 MK2-23 variable regions covalently linked to human immunoglobulin constant regions enhanced mAb MK2-2

28 tural ACE2 collectrin domain and fusion to a human immunoglobulin crystallizable fragment (Fc) domain

29 Human immunoglobulin D (IgD) occurs most abundantly as a

30 ed the ability of this mutant strain to bind human immunoglobulin D.

31 cs and a T cell-expansion system to identify human immunoglobulin-derived peptides capable of inducin

32 vide novel insight into the action of pooled human immunoglobulin during invasive S. pyogenes infecti

33 d by detecting human immunoglobulin G (IgG), human immunoglobulin E (IgE) and Aspergillus fumigatus a

34 biosensor, featuring a highly specific anti-human immunoglobulin E (IgE) aptamer as a capture probe,

35 aptamer-based biosensor for the detection of human immunoglobulin E (IgE) is developed using the elec

36 The human immunoglobulin E antibody responses to the group 1

37 d in the A-B loop of the Cepsilon3 domain of human immunoglobulin E has been carried out.

38 o extend the concept to humans, we immunized human immunoglobulin-expressing mice with human DEC205 (

39 was immunocaptured by immobilized goat anti-human immunoglobulin Fc(gamma) antibody resin, and the c

40 d MAPs were found in a preparation of normal human immunoglobulin for intravenous use.

41 our center who received orally administered human immunoglobulin for norovirus enteritis, and it app

42 An obtained scFv was converted into human immunoglobulin formats including IgE.

43 aluate the efficacy of a soluble murine RANK-human immunoglobulin fusion protein (muRANK.Fc) as a bon

44 nd-analyte binding interactions between anti-human immunoglobulin G (anti-hIgG) and human immunoglobu

45 ngle-wall carbon nanotubes (SWCNTs) and anti-human immunoglobulin G (anti-HIgG) is reported herein.

46 Such pairs include (i) human immunoglobulin G (H-IgG)-fluorophore-labeled anti-

47 itive binding proteins for the Fc portion of human immunoglobulin G (hIgG) (hFc) using two different

48 Control samples containing a nonspecific human immunoglobulin G (hIgG) antibody were also studied

49 onitor and characterize the AGE formation of human immunoglobulin G (hIgG) by MG and G using ultravio

50 -1) virions and HSV-1-infected cells bind to human immunoglobulin G (hIgG) via its Fc region.

51 rker proteins (human serum albumin (HSA) and human immunoglobulin G (HIgG)) and achieved an ultralow

52 anti-human immunoglobulin G (anti-hIgG) and human immunoglobulin G (hIgG).

53 In an in vitro neutralization assay using human immunoglobulin G (IgG) (intravenous immune globuli

54 Group 2 mice were actively immunized with human immunoglobulin G (IgG) anti-cardiolipin antibodies

55 Human immunoglobulin G (IgG) antibodies are a major clas

56 e of S. pyogenes), a proteinase that cleaves human immunoglobulin G (IgG) antibodies in the hinge reg

57 rk demonstrates a 5 min quantitation of most human immunoglobulin G (IgG) antibodies through capture

58 Human immunoglobulin G (IgG) autoantibodies to glycine r

59 orescence of an immunoassay of Protein A and human immunoglobulin G (IgG) by over 7400-fold and the i

60 resenting amino acids 106 to 138 of CAP18 to human immunoglobulin G (IgG) by using the heterobifuncti

61 domains of growth factor receptors fused to human immunoglobulin G (IgG) Fc were incubated with para

62 cells (IPEC) were incubated with polyclonal human immunoglobulin G (IgG) for 6 days before incubatio

63 We used pooled human immunoglobulin G (IgG) from HIV-negative donors to

64 ate neutralization, a panel of 12 anti-HIV-1 human immunoglobulin G (IgG) MAbs, specific for epitopes

65 ell-redirecting domain to any off-the-shelf, human immunoglobulin G (IgG) or native IgG isolated from

66 Heat maps for human immunoglobulin G (IgG) responses for each village

67 the efficacies of anti-GXM MAbs of the four human immunoglobulin G (IgG) subclasses, which have iden

68 In this study, human immunoglobulin G (IgG) that had previously been sh

69 We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antib

70 immunosensor for the sensitive detection of human immunoglobulin G (IgG) was prepared based on gold

71 Three-dimensional (3D) ordered arrays of human immunoglobulin G (IgG) were fabricated using well-

72 Enzymatically released N-glycans from human immunoglobulin G (IgG) were used as the test sampl

73 y of APPmicroTP is demonstrated by detecting human immunoglobulin G (IgG), human immunoglobulin E (Ig

74 in vitro, in the presence of high levels of human immunoglobulin G (IgG), in the serum of patients r

75 precipitated complex of GB1 with full length human immunoglobulin G (IgG).

76 has cysteine endopeptidase activity against human immunoglobulin G (IgG).

77 ntly linked to human serum albumin (HSA) and human immunoglobulin G (IgG).

78 e fragment crystallizable (Fc) region of the human immunoglobulin G (IgG).

79 orption is reported for selective binding of human immunoglobulin G (IgG).

80 ressed, the genes encode proteins which bind human immunoglobulin G (Mrp50 and EmmL50) or immunoglobu

81 Human immunoglobulin G 1 variants of the murine TRALI-in

82 Multiplexed assay of human immunoglobulin G and M (IgG and IgM) antibodies wi

83 esign complementarity determining regions of human Immunoglobulin G antibodies with target affinities

84 e designed our assay using a monoclonal anti-human immunoglobulin G antibody bound to the solid phase

85 A significantly higher human immunoglobulin G antibody response and the highest

86 east 3 Gag peptides, and high titers of anti-human immunoglobulin G antibody were made.

87 acterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon.

88 rminal to the heavy-chain constant region of human immunoglobulin G containing the Fc receptor bindin

89 ibited by the addition of a Fc-specific anti-human immunoglobulin G Fab fragment to the virus-antibod

90 se cleavage site that, in turn, is linked to human immunoglobulin G Fc.

91 Recent advances enabling the cloning of human immunoglobulin G genes have proven effective for d

92 Picomolar detection of human immunoglobulin G has been realized using particle

93 the extracellular part of layilin joined to human immunoglobulin G heavy chain and used this chimera

94 ed as a fusion product with the Fc domain of human immunoglobulin G heavy chain gamma1 (gB-Fc) in an

95 The hinge region on the Fc fragment of human immunoglobulin G interacts with at least four diff

96 Human immunoglobulin G isotype 4 (IgG4) antibodies (Abs)

97 demands highly specific discrimination from human immunoglobulin G naturally present in the blood.

98 Human immunoglobulin G subclass 3 (IgG3) possesses a uni

99 Binding studies with polyclonal human immunoglobulin G suggest that the antibody respons

100 um samples from vaccinated animals contained human immunoglobulin G that reacted with HIV-1 Env prote

101 ecruit the fragment crystallizable region of human immunoglobulin G via their A-repeat regions to the

102 IL-17R:Fc or control human immunoglobulin G was administered i.p. (500 microg

103 Rituximab, a chimeric human immunoglobulin G(1) (IgG(1)) anti-CD20 monoclonal

104 We demonstrated with albumin, human immunoglobulin G, and an anti-COVID monoclonal ant

105 horse radish peroxidase, chicken avidin, and human immunoglobulin G, respectively.

106 of a model protein in human serum, that is, human immunoglobulin G, with the aim to demonstrate a vi

107 receptors 1 and 2 fused to the Fc portion of human immunoglobulin G.

108 tips also enrich glycans from ovalbumin and human immunoglobulin G.

109 f detection 10ng/ml) and selectivity towards human immunoglobulin G.

110 detection ~10ng/ml) and selectivity towards human immunoglobulin G.

111 ine serum albumin, and high-molecular weight human immunoglobulin G.

112 single-cell cloning and expression of fully human immunoglobulin-G.

113 he BZLF2 protein linked to the Fc portion of human immunoglobulin G1 (BZLF2.Fc) was expressed from ma

114 The quantitative analysis of human immunoglobulin G1 (hIgG1) by mass spectrometry is

115 ype forms of obinutuzumab, particularly when human immunoglobulin G1 (hIgG1) mAbs were compared.

116 R) (p80) domains linked to the Fc portion of human immunoglobulin G1 (huTNFR:Fc).

117 Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody tar

118 age display library to generate IMC-41A10, a human immunoglobulin G1 (IgG1) antibody that binds with

119 Human immunoglobulin G1 (IgG1) contains 12 domains, and

120 igh-mannose glycan-binding lectin Avaren and human immunoglobulin G1 (IgG1) Fc (AvFc) selectively rec

121 pathogenic domains of Dsg3 linked to either human immunoglobulin G1 (IgG1) or mouse IgG2a (Dsg3-Fc).

122 racellular domain fused to the Fc portion of human immunoglobulin G1 (IgG1), and growth factors stem

123 clinical trials are chimeric, humanized, and human immunoglobulin G1 (IgG1).

124 ed with ACI blood (RT1a) together with L6 (a human immunoglobulin G1 [IgG1] antibody as isotype contr

125 Chimeric mAb 2C7 (human immunoglobulin G1 [IgG1]) with an E430G Fc modific

126 requires priming of NK cells by immobilized human immunoglobulin G1 and costimulation through CD137L

127 d #8 CLL clones were prepared as recombinant human immunoglobulin G1 and used as primary antibodies i

128 Ramucirumab is a human immunoglobulin G1 antibody that binds vascular end

129 An Fn14-specific blocking human immunoglobulin G1 antibody variant with compromise

130 mmaRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent c

131 tumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody.

132 citumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that co

133 typing, resulted in an affinity enhanced VHH-human immunoglobulin G1 Fc fusion molecule with subnanom

134 ted was then recombinantly engineered with a human immunoglobulin G1 Fc region to construct the fully

135 ugate that is stably linked to a proprietary human immunoglobulin G1 Fc with a long half-life for pre

136 Guselkumab is a fully human immunoglobulin G1 lambda monoclonal antibody that

137 ropic envelope protein to the Fc region of a human immunoglobulin G1 molecule for use in binding assa

138 We recently developed anti-OspA human immunoglobulin G1 monoclonal antibodies (HuMAbs) t

139 irus plaque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at

140 We examined here whether a fully human immunoglobulin G1 monoclonal antibody (MAb) specif

141 Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed aga

142 at and exploiting the stable architecture of human immunoglobulin G1 We used iterative experimental v

143 2b) or its humanized derivative, CAMPATH-1H (human immunoglobulin G1).

144 gle-chain Fv antibody fragments fused to the human immunoglobulin G1-derived Fc fragment under the co

145 ain was fused in frame with the Fc domain of human immunoglobulin G1.

146 ke domain of MHVR fused to the Fc portion of human immunoglobulin G1.

147 ed disulfide-mediated structural variants of human immunoglobulin G2 (IgG2) antibodies was recently t

148 ilized hybridoma technology to produce fully human immunoglobulin G2 (IgG2) MAbs from B cells of an i

149 Human immunoglobulin G2 (IgG2) responses are gamma inter

150 Human immunoglobulin G2 (IgG2) serum concentrations and

151 ized by Dob1, which is a hybridoma-secreting human immunoglobulin G2 antibody to the PS of serotype 6

152 The anti-PS human immunoglobulin G2 MAb made from mice immunized wit

153 onjugate glembatumumab vedotin links a fully human immunoglobulin G2 monoclonal antibody against the

154 Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds t

155 aluate safety and efficacy of astegolimab, a human immunoglobulin G2 monoclonal antibody that selecti

156 Panitumumab (P) is a fully human, immunoglobulin G2 monoclonal antibody targeting e

157 Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclona

158 ace molecule on immune cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumo

159 Garadacimab is a fully human immunoglobulin G4 monoclonal antibody targeting ac

160 Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkp

161 Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkp

162 Nivolumab is a fully human immunoglobulin G4 programmed death-1 immune checkp

163 Nivolumab, a human immunoglobulin G4-blocking antibody against the T-

164 sence of histidine also enhanced cleavage of human immunoglobulin gamma (IgG) molecules containing a

165 relation with SEC and can be applied to both human immunoglobulin gamma 1 (IgG1) and IgG2 antibodies.

166 he large cleavage product of Pref-1 fused to human immunoglobulin-gamma constant region.

167 o antibodies revealed the versatility of the human immunoglobulin gene segment D3-3 (IGHD-3-3) in rec

168 We further tested these programs using 30 human immunoglobulin genes from Genbank and here highlig

169 Mice transgenic for human immunoglobulin genes were immunized with OspA from

170 Transgenic mice with human immunoglobulin genes were immunized with the recom

171 Transgenic mice carrying human immunoglobulin genes were used to isolate HuMAbs t

172 tibodies, H2L2 Harbor Mice(R), which express human immunoglobulin germline genes, were immunized with

173 tion sites are found in approximately 20% of human immunoglobulin Gs (IgGs) in addition to the conser

174 Amplification of human immunoglobulin has many potential applications suc

175 ome vector carrying the entire unrearranged, human immunoglobulin heavy (hIGH) and kappa-light (hIGK)

176 Transgenic mice have been created that carry human immunoglobulin heavy and light chain genes in germ

177 mbinatorial phage display library expressing human immunoglobulin heavy and light chain variable regi

178 re we describe a method for amplification of human immunoglobulin heavy and light chains from single

179 o elk-1-related processed pseudogenes in the human immunoglobulin heavy chain (IgH) locus, accounting

180 d a distinct RNA transcriptome signature and human immunoglobulin heavy chain (VH) repertoire that wa

181 ucleotide 5'non-coding region (5'NCR) of the human immunoglobulin heavy chain binding protein (BiP) m

182 The 5'-non-translated regions (5'NTR) of human immunoglobulin heavy chain binding protein (BiP),

183 To investigate regulation of human immunoglobulin heavy chain expression, we have clo

184 n vivo interaction of these factors with the human immunoglobulin heavy chain gene enhancer regions i

185 The human immunoglobulin heavy chain locus contains 39 funct

186 The highly repetitive human immunoglobulin heavy chain sequence was analyzed u

187 Genetic diversity within the human immunoglobulin heavy-chain (IGH) locus influences

188 f the IL-4 response element derived from the human immunoglobulin heavy-chain germ line epsilon promo

189 -order interactions on single alleles of the human immunoglobulin heavy-chain locus (IGH) using Tri-C

190 fic immunoglobulin, 111In-labeled polyclonal human immunoglobulin (HIG) was separately administered t

191 e glycoproteins, and a high-titer anti-HIV-1 human immunoglobulin (HIVIG) preparation for their abili

192 VlacZ with coadministration of 200 microg of human immunoglobulin (Ig) G or CTLA4Ig by intraperitonea

193 MAU868 is a novel, human immunoglobulin (Ig) G1 monoclonal antibody that bi

194 HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against

195 Tralokinumab is a fully human immunoglobulin (Ig) G4 monoclonal antibody that bi

196 Human immunoglobulin (Ig) G4 usually displays antiinflam

197 icial chromosome (HAC) comprising the entire human immunoglobulin (Ig) gene repertoire in the germlin

198 CRISPR-Cas9 technology to edit the mouse and human immunoglobulin (Ig) genes.

199 Transgenic mice bearing unrearranged human immunoglobulin (Ig) heavy and kappa light chain lo

200 In this study, we utilized a panel of human immunoglobulin (Ig) IgA monoclonal antibodies isol

201 ppropriate precursors in mice transgenic for human immunoglobulin (Ig) loci.

202 hnology, XenoMouse, that contains 80% of the human immunoglobulin (Ig) variable gene repertoire and c

203 y was to determine the antiviral efficacy of human immunoglobulin (Ig), a preparation of highly purif

204 Human immunoglobulin (Ig)A exists in blood as two isotyp

205 osolic domains each mediated rapid uptake of human immunoglobulin (Ig)G followed by recycling of inta

206 The release kinetics for human immunoglobulin (IgG) through the permeable structu

207 albumin (BSA), transferrin factor (TF), and human immunoglobulins (IgG) are utilized as exemplary sa

208 ray crystal structure of intact, full-length human immunoglobulin (IgG4) at 1.8 angstrom resolution.

209 s recognized by the antibodies in the pooled human immunoglobulin (IgGs), reflecting natural occurren

210 y immunologist with a bird's eye view of how human immunoglobulins (Igs) came into existence and subs

211 ell development and to support production of human immunoglobulins (Igs), major differences in the ef

212 We have investigated the effect of human immunoglobulin in an animal model of Guillain-Barr

213 Importantly, passive transfer of pooled human immunoglobulin into mice does not interfere with t

214 Human immunoglobulin is an effective treatment for Guill

215 Pooled human immunoglobulin is widely advocated as an adjunctiv

216 we moved to a therapy based on IgM-enriched human immunoglobulins (IVIG), repeated every 4 weeks, an

217 We recently completed a map of the human immunoglobulin lambda (IGL) locus on chromosome 22

218 Host targets, including human immunoglobulin lambda locus (IGL), cytochrome c ox

219 ing 15 functional Vlambda segments) from the human immunoglobulin lambda locus.

220 e models, DARIC T cells regulated peripheral human immunoglobulin levels through specific elimination

221 eins by studying the effects of mutations of human immunoglobulin light chain variable domain (V(L)).

222 (H-D) exchange rates) and the propensity of human immunoglobulin light chains to form amyloid fibril

223 discriminating between benign and pathologic human immunoglobulin light chains.

224 nformational dynamics of a pathogenic kappa4 human immunoglobulin light-chain variable domain, SMA, a

225 Here we report the crystal structure of the human immunoglobulin-like NK cell receptor KIR2DL2 in co

226 l with or without CpG to mice transgenic for human immunoglobulin loci (XenoMouse mice) and expressin

227 ated from transgenic mice reconstituted with human immunoglobulin loci (XenoMouse mice) vaccinated wi

228 ce and transchromosomic (Tc) cattle carrying human immunoglobulin loci are too low for therapeutic ap

229 nic mice with large portions of unrearranged human immunoglobulin loci can produce fully human antige

230 se in mice, by introducing nearly the entire human immunoglobulin loci into the germ line of mice wit

231 sgenic mice reconstituted with megabase-size human immunoglobulin loci to generate a human MAb agains

232 munization via Pfs25 virus-like particles in human immunoglobulin loci transgenic mice.

233 sponse of transgenic mice reconstituted with human immunoglobulin loci, XenoMouse, to PPS antigens in

234 genetically modified mice expressing diverse human immunoglobulin loci, ZIKV CC_FLE sE induces robust

235 Transgenic mice with the complete human immunoglobulin locus enable studies of controlled

236 its for the detection of Toxoplasma-specific human immunoglobulin M (IgM) antibodies, an FDA-sponsore

237 Between 5- and 10-fold more purified human immunoglobulin M (IgM) but not IgG was deposited o

238 conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold.

239 The human immunoglobulin M (lambda) GXM monoclonal antibody

240 XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and kappa) which wer

241 Eliminating SLA-DQ reduced human immunoglobulin M and IgG binding to primary pig ce

242 n vitro and suggest that the hypothesis that human immunoglobulins may affect C. neoformans virulence

243 Immunoglobulin A (IgA), the most abundant human immunoglobulin, mediates immune protection at muco

244 bulin fusion protein (LTbetaR-Ig) or control human immunoglobulin on days embryonic day 11 (E11) and

245 lence mechanism, we determined the effect of human immunoglobulins on C. neoformans titan cell format

246 coccal surface proteins recognised by pooled human immunoglobulin permitted identification and rankin

247 Human immunoglobulin preparations for intravenous or sub

248 e platform technology that can produce fully human immunoglobulins rapidly, and in substantial quanti

249 ls but not in unprotected individuals, using human immunoglobulin reactivity data obtained from prote

250 The crystal structure of a human immunoglobulin receptor, FcgammaRIIIb, has been de

251 able to generate a humanized variant using a human immunoglobulin scaffold that shares a high degree

252 Similarly, pooled human immunoglobulin specifically inhibited nuclease act

253 ce standards, and no differentiation between human immunoglobulin subclasses.

254 similar fusion protein that, instead, had a human immunoglobulin tail.

255 Antibody VRC01 is a human immunoglobulin that neutralizes about 90% of HIV-1

256 e immunoglobulins are virtually identical to human immunoglobulins, these chimpanzee anticapsid MAbs

257 We describe a novel strain of human immunoglobulin transgenic mice and the use of this

258 Human immunoglobulin transgenic mice provide a method of

259 man antibody response with VH3 expression in human immunoglobulin transgenic mice that has been obser

260 ously constrained to individual user-defined human immunoglobulin variable heavy-chain (V(H)) genes,

261 ally engineered mice that have a full set of human immunoglobulin variable region genes.

262 Partitioning the human immunoglobulin variable region into variable (V),

263 onic stem cells, we have inserted the entire human immunoglobulin variable-gene repertoire (2.7 Mb) i

264 The expressed human immunoglobulin Vlambda repertoire demonstrates a s

265 uclease B, human transferrin, and polyclonal human immunoglobulin was rapidly achieved in a few minut

266 e a >300 kDa complex of GB1 with full-length human immunoglobulin, where we found that sample prepara

267 ial got underway to evaluate the efficacy of human immunoglobulin with high titers of antibodies to W

268 ent tetravalent form of ACE2, coupled to the human immunoglobulin y1 Fc region, using a self-assembli